Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 28(20): 115730, 2020 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-33069073

RESUMO

The anthracenone ligands (1-12) with a keto-phenol and a hydroxamic acid unit were synthesized and evaluated by a restriction enzyme inhibition assay. DNA substrates composed of multiple CGCG or CGG sites are fully hydrolyzed by a restriction enzyme that is selective for each sequence. Under such conditions, the full-length DNA substrate remains only when the ligand binds to all binding sites and protects it from hydrolysis by the restriction enzymes. In the assay using AccII and the 50-mer DNA substrates containing a different number of CGCG sites at different non-binding AT base pair intervals, the more the CGCG sites, the more the full-length DNA increased. Namely, simultaneous binding of the ligand (5) to the CGCG sites increased in the order of (CGCG)5>(CGCG)2>(CGCG)1. Furthermore, the length of the spacer of the hydroxamic acid to the anthracenone skeleton played an important role in the preference for the number of the d(A/T) base pairs between the CGCG sites. The long spacer-ligand (5) showed a preference to the CGCG sites with five AT pairs, and the short spacer-ligand (10) to that with two AT pairs. The ligand (12) with the shortest spacer showed a preference in simultaneous binding to the 54-mer DNA composed of 16 continuous CGG sites in the assay using the restriction enzyme Fnu4HI that hydrolyzes the d(GCGGC)/d(CGCCG) site. Application of these ligands to biological systems including the repeat DNA sequence should be of significant interest.


Assuntos
Antracenos/farmacologia , Enzimas de Restrição do DNA/antagonistas & inibidores , Ácidos Hidroxâmicos/farmacologia , Fenóis/farmacologia , Antracenos/síntese química , Antracenos/química , Sítios de Ligação/efeitos dos fármacos , Enzimas de Restrição do DNA/metabolismo , Relação Dose-Resposta a Droga , Ácidos Hidroxâmicos/química , Ligantes , Estrutura Molecular , Fenóis/química , Relação Estrutura-Atividade , Especificidade por Substrato
2.
Bioorg Med Chem Lett ; 28(10): 1832-1835, 2018 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-29657103

RESUMO

Chromomycin A3 (CMA3) is an aureolic acid-type antitumor antibiotic. CMA3 forms dimeric complexes with divalent cations, such as Mg2+, which strongly binds to the GC rich sequence of DNA to inhibit DNA replication and transcription. In this study, the binding property of CMA3 to the DNA sequence containing multiple GC-rich binding sites was investigated by measuring the protection from hydrolysis by the restriction enzymes, AccII and Fnu4HI, for the center of the CGCG site and the 5'-GC↓GGC site, respectively. In contrast to the standard DNase I footprinting method, the DNA substrates are fully hydrolyzed by the restriction enzymes, therefore, the full protection of DNA at all the cleavable sites indicates that CMA3 simultaneously binds to all the binding sites. The restriction enzyme assay has suggested that CMA3 has a high tendency to bind the successive CGCG sites and the CGG repeat.


Assuntos
Cromomicina A3/metabolismo , DNA/metabolismo , Desoxirribonucleases de Sítio Específico do Tipo II/metabolismo , Sequência de Bases , Sítios de Ligação , Cromomicina A3/química , DNA/química , Dimerização , Ensaios Enzimáticos , Magnésio/química , Ressonância de Plasmônio de Superfície
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...